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Although Respiratory syncytial virus (RSV)
bronchiolitis is the most important cause of
hospital admission for infants during the winter
season, the pathogenesis is largely unknown.
Interleukin-17 (IL-17) concentrations were
studied in nasopharyngeal aspirates from 21
non-ventilated and 17 ventilated infants admi-
tted to hospital with RSV bronchiolitis at time
of admission and discharge from the hospital.
On admission, nasopharyngeal concentrations
of most cytokines and chemokines were lower
in non-ventilated infants than in ventilated
infants, reaching statistical signiﬁcance for
Eotaxin, IL-1a, and IL-6. During course of dis-
ease, nasopharyngeal concentrations of most
cytokines and chemokines decreased, reaching
statistical signiﬁcance for IL-6 and IP-10.
However, nasopharyngeal IL-17 concentrations
were higher at discharge than at admission
in children with non-ventilated RSV disease
(209–101 pg/ml, P ¼ 0.008), a response pattern
not observed in ventilated RSV patients nor for
other cytokines or chemokines. It is speculated
that local IL-17 production may be involved
during convalescence from RSV bronchiolitis in
non-ventilated patients by facilitating innate
and adaptive antiviral immune responses. The
role of IL-17 in the pathogenesis of RSV
bronchiolitis is to be explored further. J. Med.
Virol. 84:1084–1088, 2012.
 2012 Wiley Periodicals, Inc.





Human respiratory syncytial virus (RSV) is a
species in the genus Pneumovirus, family
Paramyxoviridae. RSV bronchiolitis is the most
common cause of hospitalization for infants during
the winter season. Prematurity, chronic lung disease,
congenital heart disease, Down’s syndrome, and neu-
romuscular disease are conditions associated with
severe course of disease [Welliver, 2003; Bloemers
et al., 2007; Resch et al., 2009]. However, most chil-
dren hospitalized for RSV bronchiolitis were healthy
until infected. Viral loads have been associated with
disease severity [DeVincenzo et al., 2005; Houben
et al., 2010]. The precise mechanisms underlying
human RSV bronchiolitis are largely unknown and
most likely multi-factorial, in which both immunologi-
cal and non-immunological responses, as well as ge-
netic susceptibility play a role.
Interleukin-17 (IL-17) or IL-17A is a member of a
family of cytokines with pro-inﬂammatory effector
function. The IL-17 family, including IL-17A to IL-
17F, represents a distinct signaling system and has
been linked to many immune and auto-immune relat-
ed diseases such as rheumatoid arthritis, lupus, allo-
graft rejection and anti-tumor immunity, and
speciﬁcally for IL-17F, allergic airway inﬂammation
and asthma [Aggarwal and Gurney, 2002; Kawaguchi
et al., 2009]. It was originally described as a product
of Th17 cells, a distinct CD4þ T-cell subset bearing
the IL-23 receptor [Korn et al., 2009]. It has now
become clear that IL-17 is produced by various cells
from the adaptive and innate immune system, such as
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gd-T-cells, Tc17 cells, and invariant natural killer
T-cells (iNKT)-cells [Korn et al., 2009; Xie et al., 2009;
Cua and Tato, 2010]. Although effector functions are
incompletely understood, it is appreciated that IL-17
is capable of inducing a speciﬁc pro-inﬂammatory im-
mune response through the production of many other
cytokines, chemokines, and prostaglandins. During
infection, IL-17 induces a tissue response required for
clearance of bacteria, viruses, and fungi, possibly
through induction of a neutrophil response [Onishi
and Gaffen, 2010]. There are only limited data on the
role of IL-17 in the defense against viral infections, in
particular against RSV infection. In the current
study, it was hypothesized that IL-17 production plays
a role during convalescence of RSV disease. IL-17 was
therefore studied during the acute phase and at recov-
ery of disease in a cohort of infants hospitalized for
RSV bronchiolitis. Differences in severity of disease
was differentiated by need for mechanical ventilation.
It was shown that local IL-17 production increases dur-
ing recovery in children with hospitalized non-ventilat-
ed RSV bronchiolitis, suggesting that IL-17 may play a
protective role against the development of severe RSV
disease requiring mechanical ventilation.
MATERIALS AND METHODS
Patients
Children aged under 13 months with symptoms of
lower respiratory tract infection admitted to the pedi-
atric ward of two hospitals in The Netherlands were
included during two consecutive winter seasons.
Symptoms of lower respiratory tract infection were se-
vere chest cough, wheezing, hoarseness, stridor,
shortness of breath, cyanosis, and apnea. Children
were included after nasopharyngeal aspirates were
found positive for RSV by direct immunoﬂuorescence,
diagnosis was later conﬁrmed by culture and polymer-
ase chain reaction (PCR). Infants born prematurely
with congenital heart disease or chronic lung disease,
infants with wheezing illness before RSV bronchiolitis
was diagnosed, and patients using corticosteroids or
bronchodilators were not included. Differences in se-
verity of RSV disease was differentiated by need for
mechanical ventilation. All infants admitted to the pe-
diatric intensive care unit were intubated and me-
chanically ventilated, therefore stay at the intensive
care unit was identical to the requirement of mechani-
cal ventilation. The study was performed in compli-
ance with relevant laws and institutional guidelines
and in accordance with the ethical standards of the
Declaration of Helsinki and approved by the local
Medical Ethics Committee at the Medical Center
Leeuwarden. All parents or guardians gave written
consent to participate in this study.
Nasopharyngeal Aspirates
Undiluted nasopharyngeal aspirates were taken
within 24 hr after admission and at discharge from
the hospital. Nasopharyngeal secretions were gently
aspirated by an experienced physician with a 3.3 mm
suction catheter, placed on ice immediately and stored
at 808 for later analysis. Xylomethazolin or NaCl
0.9% nasal spray was not given in the 6 hr prior to
aspiration. Cytokine and chemokine concentrations
were measured in all aspirates using a highly speciﬁc
multiplex assay [De Jager et al., 2003]. Sample collec-
tion and processing has been described previously
[Bont et al., 2001; Schuurhof et al., 2011]. Samples
were weighed, diluted as necessary, sonicated, centri-
fuged, and duplicate assays were performed on each.
In addition to IL-17 (detection limit 10–5,000 pg/ml),
the following cytokine and chemokine concentrations
were measured: Eotaxin, IL-1a, IL-6, Interferon (IFN)
inducible protein 10 (IP-10), IL-1b, Monokine induced
by IFN-g (MIG), macrophage inﬂammatory protein 1a
(MIP-1a), soluble intercellular adhesion molecule 1
(sICAM1), and IFN-g (detection limits 5–5,000 pg/ml).
Statistical Analysis
Paired cytokine and chemokine concentrations at
time of admission in non-ventilated and ventilated
infants were compared by Mann–Whitney U test.
Mann–Whitney U test was also used to compare
paired cytokine and chemokine concentrations at time
of admission versus time of discharge from the hospi-
tal in both non-ventilated and ventilated patients. All
tests of signiﬁcance were two-sided. P-values < 0.05
were considered to be statistically signiﬁcant.
RESULTS
The patients investigated consisted of 21 non-me-
chanically ventilated infants and 17 mechanically
ventilated infants. Except for length of hospital stay,
no signiﬁcant differences were found in baseline
characteristics between infants with or without need
for mechanical ventilation. There was an equal distri-
bution of male infants in both groups (43% vs. 59%).
The median age at time of admission and the percent-
age of infants born prematurely before 37 weeks ges-
tation was similar in non-ventilated and ventilated
infants (14 vs. 9 weeks, and 14% vs. 29%, respective-
ly). In both groups, a similar number of children had
been ill 3 days before admission (76% vs. 53%).
Median length of hospital stay was signiﬁcantly
longer in children with severe RSV disease requiring
mechanical ventilation (6 days vs. 10 days; Table I).
Concentrations of IFN-g were below the level of detec-
tion in all samples. For each inﬂammatory mediator,
analyses were made comparing time of admission to
discharge in non-ventilated as well as ventilated
patients. Furthermore, cytokine and chemokine con-
centrations at time of admission were compared in
both groups. Finally, an attempt was made to analyze
emerging patterns during course of disease. At time of
admission, there was no difference in IL-17 concentra-
tion between non-ventilated and ventilated infants
(101 pg/ml vs. 72 pg/ml; not signiﬁcant). Median
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nasopharyngeal concentrations of Eotaxin, IL-1a, and
IL-6 were lower in non-ventilated patients (18 vs.
118 pg/ml, 368 vs. 4,001 pg/ml, 362 vs. 12,500 pg/ml,
respectively; P < 0.001). IL-17 concentrations were
signiﬁcantly higher at discharge than at admission
(209 pg/ml vs. 101 pg/ml; P ¼ 0.0083) in non-ventilat-
ed infants. IL-17 concentrations did not increase dur-
ing course of disease in ventilated infants (Fig. 1).
Concentrations of other cytokines and chemokines fol-
lowed equal patterns in both groups, and either de-
creased (P < 0.05 for IL-6 and IP-10) or remained
stable (P  0.05 for Eotaxin, IL-1a, IL-1b, MIG,
MIP1a, and sICAM1) during hospitalization
(Table II). In both ventilated and non-ventilated
infants, length of hospital stay was not correlated to
IL17 concentration at discharge. Furthermore, length
of hospital stay was not correlated to the difference in
IL17 concentration between admission and discharge.
Age at admission was not correlated to IL17 concen-
tration at time of admission nor at time of discharge.
DISCUSSION
In this study, local IL-17 production increased dur-
ing the course of disease in non-ventilated infants with
RSV bronchiolitis. Other inﬂammatory mediators
either decreased or remained stable during course of
disease in both ventilated and non-ventilated infants.
These results could suggest that local IL-17 may play a
protective role against the development of severe RSV
bronchiolitis requiring mechanical ventilation. Fur-
thermore, it implies that mechanisms that determine
disease severity are apparently different than those
that are involved in resolution of disease.
At time of admission, children requiring mechanical
ventilation for RSV disease had higher levels of
Eotaxin, IL-1a, and IL-6. Although it is not known
whether cytokine concentrations are effected by me-
chanical ventilation, these results are in accordance
with previous research showing high initial concen-
trations of pro-inﬂammatory mediators in children
with most severe disease [Sheeran et al., 1999; Gara-
falo et al., 2001; Smyth et al., 2002; Welliver et al.,
2002; McNamara et al., 2004]. Therefore, this study
conﬁrms that development of more severe RSV bron-
chiolitis is associated with a more robust cascade of
inﬂammatory responses. Because most of these medi-
ators can be produced by airway epithelium in re-
sponse to RSV infection, this observation suggests, as
is generally accepted in the case of RSV, a critical role
for the epithelium as a ﬁrst line of defence [McNa-
mara et al., 2003].
IL-17 is a pleiotropic cytokine, originally thought to
be produced only by T-cells, but is now known to be
produced by innate immune cells, such as dendritic
cells, iNKT and as gd-T-cells. The IL-17 receptor is
expressed ubiquitously in many tissues, including the
lungs [Cua and Tato, 2010]. The role of IL-17 in host
defence against viruses is understood incompletely. In
general, antiviral defence depends heavily on type I
IFNs, which are not known to be regulated by IL-17.
Nevertheless, during experimental inﬂuenza infec-
tion, IL-17 production by CD8þ T-cells protects mice
against disease and death [McKinstry et al., 2009; Xie
et al., 2009; Onishi and Gaffen, 2010]. In this study,
IL-17 increases during the course of disease in
TABLE I. Subject Characteristics
Non-ventilated





Number of male infants 9 (43%) 10 (59%) NSa
Prematurity (amenorrhoe <37 weeks of gestation) 3 (14%) 5 (29%) NSa
Age at admission (median in weeks after birth (CI)) 14 (13–26) 9 (6–29) NSb
Symptoms 3 days before admission 16 (76%) 9 (53%) NSa
Length of hospital stay (median in days (min-max)) 6 (3–13) 10 (5–28) P < 0.001b
Length of ventilation (median in days (min-max)) NA 9 (5–16)
NS, not signiﬁcant; NA, not applicable to non-ventilated infants.
aFisher’s exact test;
bMann–Whitney U test.
Fig. 1. Local IL-17 concentration increases during course of dis-
ease in non-ventilated infants with RSV bronchiolitis. IL17 concen-
tration increases from time of admission to discharge from the
hospital in 19 out of 21 (90%) non-ventilated children hospitalized
for RSV bronchiolitis (median 101–209 pg/ml; P ¼ 0.0083) and
remains stable in ventilated infants (median 72–41 pg/ml; not
signiﬁcant).
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children with less severe RSV disease. This is in ac-
cordance with a recent study in which plasma IL-17
could not be detected in healthy children, and the
highest concentration was found in moderately ill
patients with RSV bronchiolitis when compared with
severe cases [Larran˜aga et al., 2009]. The source of
IL-17 and the precise mechanism underlying local IL-
17 production are not known and it remains unclear
why the IL-17 response does not occur in ventilated
children. It can be considered that adaptive immune
cells, such as gd-T-cells or Tc17 cells, are the source of
increased IL-17 production. Another study did show
increased IL-17 levels in tracheal aspirate samples
from severely ill infants with RSV infection [Mukher-
jee et al., 2011]. The power of our study may have
been too small to detect differences in this subpopula-
tion. In addition, these children are generally younger
and they may have different mechanisms of viral
clearance. Also, it is not known whether intubation
and mechanical ventilation itself have an effect on
production of IL-17.
This study is the ﬁrst attempt to measure local cyto-
kine proﬁles during the course of disease in ventilated
and non-ventilated patients with RSV bronchiolitis. A
unique response pattern of IL-17 was identiﬁed which
contrasts with other pro-inﬂammatory cytokines and
chemokines that are associated with initial disease se-
verity and generally decrease during the course of dis-
ease. In addition, the use of nasopharyngeal aspirate
allowed for a measurement of absolute cytokine con-
centrations, which is not possible using other techni-
ques, such as nasal washes. And although the
association between nasopharyngeal aspirate cytokine
concentrations and endotracheal cytokine concentra-
tions is high [Joshi et al., 1998; Bont et al., 2001]
there are unknown variables to be kept in mind when
interpreting results that may inﬂuence mucus secre-
tion, such as mechanical ventilation and respiration
rate. Also, as the time between admission and dis-
charge and hence the time between measurements is
shorter in non-ventilated patients when compared to
ventilated patients, this may potentially introduce a
systemic error. Cytokine and chemokine response is a
dynamic process and differences in sampling time
may have a distorting effect. A further study limita-
tion is the absence of proof that the increase in local
IL-17 levels during the course of RSV bronchiolitis is
causally related to less severe disease. In addition,
the relatively small study population did not allow for
extensive regression analysis to study potential con-
founders, in particular age, premature birth, length of
hospital stay, and mechanical ventilation. Yet it is
reassuring that length of hospital stay is not correlat-
ed to IL-17 concentration at discharge, nor to differ-
ences in concentration between admission and
discharge. And although age at admission is an im-
portant variable to consider, it was not correlated to
IL-17 concentration at time of admission nor at time
of discharge. Another limitation in this study is not to
have considered the quantiﬁcation of viral load from
respiratory secretions that would have allowed corre-
lation of clinical and immunologic data.
In conclusion, IL-17 levels in the airways of RSV
bronchiolitis patients increase during the course of
TABLE II. Chemokine and Cytokine Analysis of Nasopharyngeal Aspirates of Ventilated and Non-Ventilated Infants With
RSV Bronchiolitis During Course of Disease
Non-ventilated infants Ventilated infants Analyses
PatternAdmission (1) Discharge (2) Admission (3) Discharge (4) P (1) vs (2) P (3) vs (4) P (1) vs (3)
IL-17 101 209 72 41 <0.05 NS NS "
56–197# 115–326 31–200 12–150
IL-6 362 47 12,500 6,666 <0.001 <0.05 <0.001 #
107–2,021 26–97 6,666–24,750 2,130–6,666
IP10 325 132 221 121 <0.05 <0.05 NS #
201–453 1–278 142–201 65–251
Eotaxin 18 22 118 137 NS NS <0.001 !
11–50 15–56 56–277 73–338
IL-1a 368 248 4,001 3,091 NS NS <0.001 !
94–868 49–1,629 2,080–9,703 1,519–7,048
IL-1b 132 130 203 111 NS NS NS !
62–176 64–282 79–254 68–177
MIG 1,173 574 1,463 1,018 NS NS NS !
545–2,229 213–1,935 788–2,272 477–1,618
MIP-1a 2,243 2,382 2,325 2,499 NS NS NS !
1,097–3,163 845–4,201 1,949–3,218 1,172–4,065
sICAM 40,459 40,986 46,820 32,982 NS NS NS !
27,889–49,966 27,117–59,873 34,314–59,871 19,303–52,253
NS, not signiﬁcant.
Cytokine concentrations in median and quartiles# in pg/ml.
In contrast to local IL17 concentrations which increase (") during course of disease in non-ventilated children with RSV (speciﬁcally
P ¼ 0.0083), other inﬂammatory mediators show the same pattern in non-ventilated and ventilated children and either decrease (#) during
course of disease, such as IL-6 and IP10, or remain stable (!) such as Eotaxin, IL-1a, IL-1b, MIG, MIP-1a and sICAM.
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disease in hospitalized non-ventilated patients, sug-
gesting a role in controlling of the disease. Further
identiﬁcation of the role of IL-17 in recovery from
RSV bronchiolitis may lead to further insights into
pathogenesis of disease.
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